NEW YORK (GenomeWeb News) – Citing concerns over the legal environment surrounding Myriad Genetics' BRACAnalysis test, Credit Suisse today downgraded the Salt Lake City-based firm's stock to Underperform from Neutral.

Separately, Piper Jaffray also sounded uncertainty over the future of the test and lowered Myriad's price target but maintained an Overweight rating on the company's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.